Results of MPE members participation in EMA survey on bortezomibMPE, Myeloma, Patient evidenceMay 3, 2019
MPE will hold a webinar on ASH 2018 highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, MyelomaJanuary 16, 2019
Daratumumab increases progression-free survival in newly diagnosed myeloma patients ineligible for transplantMyelomaDecember 5, 2018
New data presented at ASH 2018 from an ongoing phase I clinical trial of CAR T cell therapy in relapsed/refractory myelomaConferences, MyelomaDecember 4, 2018
WECAN workgroup of patient advocates and industry experts releases guiding principles for reasonable legal agreements between patient advocates and pharmaceutical companiesMPENovember 28, 2018
